Drugs / iN1011-N17
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06218784 | Nov 2022 → Jul 2024 | chronic pain syndrome, osteoarthritis, postherpetic neuralgia | iN Therapeutics Co., Ltd. | Unknown | No outcome recorded |
| Phase 1 | NCT05496205 | Sep 2020 → Oct 2023 | chronic pain syndrome, neuropathy, painful, osteoarthritis, postherpetic neuralgia | iN Therapeutics Co., Ltd. | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 1
| Date | Issuer | Release |
|---|---|---|
| 2022-01-10 | iN Therapeutics Co., Ltd. | Results 아이엔, 'NAV 1.7 저해제' 1상 "차별성 Key데이터" 공개 intherapeutics.com ↗
아이엔테라퓨틱스가 비마약성 골관절염 통증치료제 후보물질의 핵심 차별성을 보여주는 전임상과 임상1상 중간분석 데이터를 첫 공개했다. |
All press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2022-01-10 | iN Therapeutics Co., Ltd. | 아이엔, 'NAV 1.7 저해제' 1상 "차별성 Key데이터" 공개 intherapeutics.com ↗ |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | iN1011-N17 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05496205 ↗ |
| Route | Oral | “After Oral Administration in Healthy Volunteers” NCT05496205 ↗ |